Lung Cancer Clinical Trial
Analgesic Efficacy of Intravenous Acetaminophen After Video-assisted Thoracic Surgery
Summary
We will study the efficacy of FDA approved intravenous (IV) acetaminophen ("Ofirmev", © 2011 Cadence Pharmaceuticals, Inc.) in reducing opioid consumption after minimally invasive thoracic surgery in a double blind randomized trial. This drug has been shown in Europe to reduce the need for patient controlled analgesia and the total dose of opioids, which have serious side effects in thoracic surgery patients. We will compare the use of IV patient-controlled morphine (PCA) in two groups of subjects in treating postoperative pain. We will determine if IV acetaminophen reduces post-operative morphine requirements (primary end point). We will also assess subject pain scores and post-operative complications associated with pain management as secondary end points. Our hypothesis is that the study arm receiving intravenous acetaminophen will have lower total morphine consumptions compared to the placebo group.
Full Description
We will study the efficacy of FDA approved intravenous (IV) acetaminophen ("Ofirmev", © 2011 Cadence Pharmaceuticals, Inc.) in reducing opioid consumption after minimally invasive thoracic surgery in a double blind randomized trial. This drug has been shown in Europe to reduce the need for patient controlled analgesia and the total dose of opioids, which have serious side effects in thoracic surgery patients. We will compare the use of IV patient-controlled morphine (PCA) in two groups of subjects in treating postoperative pain. One group of subjects will receive IV acetaminophen every six hours beginning within 30 minutes before surgical end time and continuing for 24 hours plus IV morphine PCA, and the other group will receive IV placebo every six hours plus IV morphine PCA, a standard treatment for postoperative pain. We will determine if IV acetaminophen reduces post-operative morphine requirements (primary end point). We will also assess subject pain scores and post-operative complications associated with pain management as secondary end points. Our hypothesis is that the study arm receiving intravenous acetaminophen will have lower total morphine consumptions compared to the placebo group.
Eligibility Criteria
Inclusion Criteria:
Any elective VATS patients with low probability of conversion to thoracotomy as determined by surgery.
Ages 18-99
American Society of Anesthesiologists Physical Status I-III, hemodynamically stable
Male or female
Exclusion Criteria:
Age less than 18.
Patient refusal
High probability of conversion to thoracotomy as determined by surgeon
Conversion of procedure to thoracotomy (subjects will be withdrawn if VATS procedure is converted to thoracotomy, as thoracotomy is more invasive and will likely require additional analgesia such as neuraxial and regional anesthesia).
Scheduled procedure of VATS Pleurodesis/decortication
History of Interstitial Lung Disease
Emergency case
Known allergy/adverse reaction to acetaminophen, morphine, or fentanyl
History of drug or alcohol abuse
Patients on preoperative analgesic therapy within one week of surgery
Contraindication to self administered morphine (unable to understand PCA)
Need for postoperative mechanical ventilation
Necessary major deviation for intraoperative study protocol as per the discretion of the intraoperative attending anesthesiologist
History of congestive heart failure, renal failure, liver failure
Pregnant or breastfeeding women
Weight less than 51 kg
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There is 1 Location for this study
New York City New York, 10065, United States
How clear is this clinincal trial information?
Please confirm you are a US based health care provider:
Yes, I am a health care Provider No, I am not a health care providerSign Up Now.
Take Control of Your Disease Journey.
Sign up now for expert patient guides, personalized treatment options, and cutting-edge insights that can help you push for the best care plan.